The HDHD5 (Haloacid Dehalogenase-like Hydrolase Domain-containing 5) antibody is a tool used to detect and study the HDHD5 protein, which belongs to the HAD (haloacid dehalogenase) superfamily of hydrolases. These enzymes typically catalyze phosphoryl transfer or hydrolysis reactions, often involved in metabolic pathways, signal transduction, or nucleic acid processing. HDHD5. also termed PGPPL1 or AGPHD1. is characterized by a conserved HAD-like hydrolase domain, though its precise biological substrates and functions remain under investigation. Emerging studies suggest roles in cellular processes such as lipid metabolism, mitochondrial function, and possibly tumorigenesis. For example, HDHD5 has been linked to prostate cancer progression and fatty acid oxidation regulation. The antibody enables researchers to explore HDHD5's expression patterns, subcellular localization (e.g., cytoplasm or mitochondria), and interactions via techniques like Western blotting, immunohistochemistry, or immunofluorescence. Its development often involves immunizing hosts with peptide antigens derived from conserved regions of the human HDHD5 protein. Validated antibodies are crucial for clarifying HDHD5's physiological and pathological relevance, particularly in metabolic diseases and cancer biology. Commercial HDHD5 antibodies are typically raised in rabbits or mice, with specificity confirmed through knockdown/knockout controls. Ongoing research aims to define HDHD5's enzymatic activity and therapeutic potential, making reliable antibodies essential for advancing this field.